Skip to main content
Premium Trial:

Request an Annual Quote

Eppendorf Array Technologies, Corning, The Regents of the University of California, Agilent Technologies, XenoPort, Maven Technologies

Eppendorf Array Technologies has received European Patent No. 1762628, "Detection method of homologous sequences differing by one base on a microarray." The patent claims a method to determine the presence or absence of single nucleotide polymorphisms at given loci of gene nucleotide sequences of an organism. The detection is particularly adapted for the identification of multiple single nucleotide polymorphisms or multiple mutations present at different gene locus, the patent claims. The method also provides tools and means to determine whether an organism is heterozygous or homozygous at a particular gene locus.

Corning has received US Patent No. 7,191,901, "Substrate container that does not degrade substrate surface." The patent claims a method of packaging slides that have a coating or monolayer on a surface and are adapted for the attachment of biomolecules to the surface. The method includes enclosing slides in a container, where slides are adapted for printing of microarrays of biomolecules and where the slides exhibit a change in water contact angle of no more than eight to 12 degrees greater than the change in water angle of slides stored in a sealed glass container after storage in the containers at room temperature for up to three months.

The Regents of the University of California of Oakland, Calif., have received US Patent No. 7,192,704, "Methods for detection and treatment of neural cancers." The patent claims a method for inhibiting proliferation of neural cells. The neural cells can be tumor cells, glial cells, neuronal cells, and cells of the central or peripheral nervous systems. The method includes contacting a neural cell with a molecule that disrupts the biological activity of a granulin molecule. The molecule may be an antibody directed against a granulin peptide, an antisense nucleotide directed against a granulin nucleic acid molecule, or a vaccine comprising a granulin peptide or a polynucleotide encoding a granulin peptide. The patent additionally claims methods for detecting and treating cancer in a neural tissue using granulin-related molecules. Also described is a method for indenting differentially expressed gene products that are translated from mRNA species, using antibody-based screening of a cDNA expression library. This method, termed differential immuno-absorption, can be coupled to cDNA microarray hybridization and used in the identification of genes that play a role in the malignant progression of cancer, the patent's abstract states.

Agilent Technologies has received US Patent No. 7,192,710, "Methods and compositions for high throughput identification of protein/nucleic acid binding pairs." The patent claims methods and compositions for high-throughput identification of protein and nucleic acid binding pairs. In the methods, a nucleic acid probe array — a molecular beacon probe array, for example — is contacted with a target nucleic acid population to produce a hybridized array. The resulting hybridized array is then contacted with a population of proteins to produce a protein-bound array. Any resulting array surface-bound target nucleic acid/protein complexes are then detected to identify protein and nucleic acid binding pairs. Systems and kits for use in practicing the methods are also claimed.

XenoPort of Santa Clara, Calif., has received US Patent No. 7,192,720, "Array-based epitope-captured antibody display." The patent claims reagents and methods for detecting target proteins in a sample. The reagents include a replicable genetic package, a protein displayed on an exterior surface of the package that is expressed from a heterologous nucleic acid borne by the package, and one or more antibodies complexed with the expressed protein and which have an open binding site for a target protein. Therefore, a segment of the nucleic acid encodes for an epitope that is shared by the expressed polypeptide and the target protein, the patent's abstract states. The reagents can be utilized individually or as part of a library or an array to bind target proteins within protein samples to form one or more complexes. By determining the sequence of the segment of the heterologous nucleic acid of a package within a complex, one can identify the target protein since the segment encodes for an epitope that is shared by the expressed and target proteins.

Maven Technologies of Los Angeles has received US Patent No. 7,193,711, "Imaging method and apparatus." The patent claims an imaging method and apparatus, including a light source emitting a polarized light beam, and an optical assembly including a control layer and a light reflection surface. The control layer allows for control over the properties of a generated evanescent wave to optimize an image of a specimen microarray within the evanescent wave. The light reflection surface includes coupling means used to couple a receptor or capture agent, allowing for flexible control over receptor specific regions.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.